Last reviewed · How we verify

Tobacco cessation pharmacotherapy

Iowa City Veterans Affairs Medical Center · Phase 2 active Small molecule

Tobacco cessation pharmacotherapy is a Small molecule drug developed by Iowa City Veterans Affairs Medical Center. It is currently in Phase 2 development.

At a glance

Generic nameTobacco cessation pharmacotherapy
SponsorIowa City Veterans Affairs Medical Center
ModalitySmall molecule
PhasePhase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Tobacco cessation pharmacotherapy

What is Tobacco cessation pharmacotherapy?

Tobacco cessation pharmacotherapy is a Small molecule drug developed by Iowa City Veterans Affairs Medical Center.

Who makes Tobacco cessation pharmacotherapy?

Tobacco cessation pharmacotherapy is developed by Iowa City Veterans Affairs Medical Center (see full Iowa City Veterans Affairs Medical Center pipeline at /company/iowa-city-veterans-affairs-medical-center).

What development phase is Tobacco cessation pharmacotherapy in?

Tobacco cessation pharmacotherapy is in Phase 2.

Related